Patrick Cashman
President
Patrick Cashman is president of USAntibiotics, the sole licensed American manufacturer of amoxicillin-based Augmentin and Amoxil solid, oral beta-lactam antibiotics and authorized generics. Based in Tennessee, he leads the team of R&D, quality, manufacturing, regulatory affairs, supply chain and commercial professionals who operate from the company’s world-class, 394,000 square foot production facility that can produce and fulfill 100 percent of the nation’s demand for these essential, life-saving medications.
With three decades in the industry, Patrick has served in executive management positions in multinational pharmaceutical organizations in the U.S., Canada and Mexico. With a focus on growth, quality and innovation, he is recognized for his knowledge and industry experience, commitment to operational excellence, delivery of exceptional client support and cultivation of high-performance teams. During his career – which includes senior leadership positions at Lundbeck, Pfizer and SmithKline Beecham – he established new subsidiaries in key markets, launched new pharmaceutical brands and led co-commercialization teams with partners around the world.
Patrick has received numerous awards, including international honors for profitability, sales growth, innovation and a new oncology business unit, while at Lundbeck Canada. His focus on patient centricity earned him the Eye for Pharma Lifetime Achievement Award. He also champions mental health awareness, having presented at the Champions of Mental Health Awards and to members of the Canadian Parliament. Patrick holds an MBA from Thunderbird School of International Business at Arizona State University and Bachelor of Science in Economics degree from the University of Wisconsin.
Traci Holt
Vice President, Accounting
Traci Holt serves as vice president of accounting at USAntibiotics, the sole licensed American manufacturer of amoxicillin-based Augmentin and Amoxil solid, oral beta-lactam antibiotics and authorized generics. In this position, she oversees all aspects of the organization’s accounting functions at its world-class, 394,000-square-foot pharmaceutical manufacturing facility in Bristol, Tennessee.
Bringing more than three decades of experience to her role, including over 15 years in the manufacturing industry, Traci has an established track record of creating and driving strategies that support financial and operational goals. At USAntibiotics, her strategic leadership and oversight spans financial disciplines, including accounting, audit, tax, financial planning, variance analysis and risk management.
Before joining USAntibiotics, Traci held an array of progressive leadership roles in manufacturing. Over the course of her career, she has managed accounting functions across four U.S.-based food manufacturers and 15 North American glass facilities, in addition to providing critical operational and warehouse management support. She began her career in public accounting.
Traci earned an MBA with a concentration in operations from Milligan College. She also holds a Bachelor in Business Administration degree from East Tennessee State University.
Steven Lutz
Vice President, Strategic Accounts
Steven Lutz is vice president of strategic accounts at USAntibiotics, the sole licensed American manufacturer of amoxicillin-based Augmentin and Amoxil solid, oral beta-lactam antibiotics and authorized generics. As an accomplished business executive, he spearheads commercial strategy to drive continued growth and market share at the company’s world-class, 394,000 square foot pharmaceutical manufacturing facility in Bristol, Tennessee.
With over three decades of experience across the pharmaceutical and biotechnology sectors, Steven brings extensive industry knowledge to his role. At USAntibiotics, he leverages his expertise to provide sales strategy and channel insight into market conditions, optimize commercial efficiency, strengthen customer relationships and oversee third-party logistics.
Steven previously served in an executive leadership role at Neos Therapeutics, where he led the organization’s vertical integration of the generic division and helped start the branded pharmaceutical division. He also co-founded Cornerstone Therapeutics in 2005, now known as Chiesi USA. During his tenure there, Steven oversaw sales, marketing, logistics and manufacturing for the company’s branded and generic products, driving exponential growth and profitability for the company.
Steven holds a Bachelor of Arts in Political Science from Moravian University.
Eric Wesoloski
Vice President, Quality and Regulatory Affairs
Eric Wesoloski is vice president of quality and regulatory affairs at USAntibiotics, the sole licensed American manufacturer of amoxicillin-based Augmentin and Amoxil solid, oral beta-lactam antibiotics and authorized generics. His responsibilities encompass all aspects of quality assurance and control, compliance, regulatory affairs and pharmacovigilance related to the manufacturing, packaging, distribution and post-marketing requirements for the company’s antibiotics.
As a global quality leader with three decades in the life sciences industry, Eric has deep expertise in building best-in-class teams and processes that foster operational excellence and adhere to the highest quality standards. During the course of his career, he’s established a reputation for spearheading robust strategies and collaborations to help ensure regulatory compliance with the U.S. Food and Drug Administration (FDA), as well as agencies in the United Kingdom and European Union.
Prior to joining USAntibiotics Eric held an array of executive leadership and technical roles in markets that include biologics, nutraceuticals, medical devices and pharmaceuticals — including positions with Regor Pharmaceuticals, Gan & Lee Pharmaceuticals, Takeda Pharmaceuticals and TransCode Therapeutics.
Eric earned his Bachelor of Science in Biology from Gannon University and MBA in Leadership Management from Indiana Wesleyan University. He is an active member of the FDA Metrics Committee, American Society for Quality and the Parenteral Drug Association, among other professional organizations.